Participants were drawn from the Women's Health Study, a completed randomized placebo-controlled trial of aspirin and vitamin E. 10
A trial fibrillation (AF) is the most prevalent cardiac rhythm disturbance encountered clinically, and the prognosis remains adverse. 1 The challenge posed by the increasing prevalence of AF is heightened by limited modalities for its prevention. Consequently, efforts aimed at identifying individuals at elevated risk for AF may provide insight into developing novel preventive therapies.
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AF and cardiovascular disease have common risk factors. 2, 3 However, low-density lipoprotein (LDL) cholesterol, which is a causal risk factor for cardiovascular disease, has been reported to have a paradoxical association with AF. 2, [4] [5] [6] Furthermore, recent mechanistic studies suggest a potentially active role for cholesterol in preventing AF, possibly through specific lipid-stabilizing effects on cell membranes. 7 This raises the question of whether the paradoxical association of LDL cholesterol with AF is because of its cholesterol component or another closely related property. Cholesterol is carried by LDL, very-low-density lipoprotein (VLDL), intermediate-density lipoprotein, lipoprotein(a), and high-density lipoprotein (HDL). These lipoproteins also carry apolipoprotein (apo) B or A-I, and differ in cholesterol content, size, and function. [7] [8] [9] Hence, characterizing the association of AF with various lipoprotein properties may provide insight into mechanisms underlying the association of LDL cholesterol with AF.
The purpose of this study was to evaluate the paradoxical association of LDL cholesterol with AF by prospectively evaluating the role of various additional lipoprotein measures with incident AF among 23 738 middle-aged and older women followed for >16 years.
Paradoxical Association of Lipoprotein Measures
With Incident Atrial Fibrillation Samia Participants were apparently healthy female healthcare professionals, aged ≥45 years, and free of prior cardiovascular disease and cancer. At enrollment, women gave written informed consent and completed questionnaires on demographics, anthropometrics, medical history, and lifestyle factors; 28 345 women also donated a blood sample. Randomized treatment ended in 2004, and women were invited to participate in continued observational follow-up. Of the women who donated a blood sample and agreed to the continued observational follow-up, 25 054 had complete baseline lipoprotein measurements. We excluded women with a history of AF (N=528) or lipid-lowering medication use (N=788) at study entry, resulting in 23 738 women for analysis. The study was approved by the institutional review board of the Brigham and Women's Hospital (Boston, MA).
Laboratory Measurements
EDTA blood samples were stored in liquid nitrogen (−170°C). Lipids and apolipoproteins were measured in a laboratory certified by the National Heart, Lung, and Blood Institute/Centers for Disease Control and Prevention Lipid Standardization program. 11, 12 Standard lipids were directly measured, and apo A-I and B were measured using immunoturbidimetric assays (DiaSorin, Stillwater, MN). Lipoprotein(a) was measured using an immunoturbidimetric assay not affected by kringle IV type-2 repeats, with reagents and calibrators from Denka Seiken (Tokyo, Japan).
Lipoprotein subclasses and size were measured by NMR spectroscopy at LipoScience, Inc (Raleigh, NC). 8, 12 High-sensitivity C-reactive protein (hsCRP), fibrinogen, soluble intercellular adhesion molecule-1, homocysteine, hemoglobin A1c, and creatinine were measured as previously described. 11
Covariates
Baseline age, race/ethnicity, menopausal status, postmenopausal hormone replacement therapy, smoking, income, education, alcohol use, exercise frequency, blood pressure, treatment for high blood pressure, and diabetes mellitus were collected from self-reported questionnaires. Body mass index (kg/m 2 ) was calculated from self-reported weight and height at baseline.
Ascertainment of Incident AF
Women were asked to report diagnoses of AF at baseline, 48 months, and annually thereafter. 3 Women who reported an event were sent a questionnaire beginning in 2006 to collect additional information. Permission was obtained to review medical records, ECGs, rhythm strips, 24-hour ECG monitoring, and information on cardiac structure and function. For deceased participants reporting AF, family members were contacted to obtain consent for medical records. An end point committee of physicians reviewed medical records according to predefined criteria. An incident AF event was confirmed if there was ECG evidence of AF or if a medical report clearly indicated a personal history of AF. Only confirmed AF events are included in this analysis.
Statistical Analysis
Statistical analyses were done using STATA. Chi-square tests and Wilcoxon rank-sum tests were used to compare categorical and continuous variables, respectively, according to incident AF. Following guidelines, 13 lipoproteins were divided into quintiles based on the distribution among women not taking hormone replacement therapy. Cox proportional hazard regression models were used to calculate hazard ratios and 95% confidence intervals.
Multivariable adjustment was done in 2 stages to assess for potential mediators and confounders. Model 1 was adjusted for age, race, trial treatment assignment, menopausal status, hormone replacement therapy, smoking, income, education, blood pressure, antihypertensive medication use, diabetes mellitus, exercise, alcohol use, and body mass index. Model 2 additionally adjusted for inflammatory/endothelial function markers (high-sensitivity C-reactive protein, fibrinogen, soluble intercellular adhesion molecule-1, and homocysteine), 
Results
During a median follow-up of 16.4 years, 795 confirmed that cases of incident AF occurred. Women who developed AF were older and had more risk factors (Table 1) . Several lipoprotein measures showed small, statistically significant differences according to incident AF. Inflammatory biomarkers were higher among women who developed AF. In unadjusted analysis ( Table 2) , several LDL measures, in particular apoB and the total number of LDL particles, were positively associated with AF. However, after adjustment, associations became inverse (hazard ratio, 95% confidence interval for top versus bottom quintile, P value): LDL cholesterol (0.72, 0.56-0.92, P=0.009), apoB (0.85, 0.65-1.11, P=0.23), the number of total LDL particles (0.77, 0.60-0.99, P=0.045), and small LDL particles (0.78, 0.61-1.00, P=0.05); all P for trend across quintiles <0.05. By contrast, the larger cholesterol-rich particles (intermediate-density lipoprotein, large LDL particles, and lipoprotein[a]) and average LDL size were not associated with AF in multivariable models. The variables that had the most impact on the directionality of the LDL cholesterol AF association were age, followed by blood pressure and body mass index, and to a smaller extent socioeconomic metrics and inflammatory biomarkers. (Table 3) generally tracked with associations seen for LDL measures. In unadjusted analysis, triglycerides and large VLDL particles and VLDL size were positively associated with AF. After adjustment, triglycerides showed a trend toward inverse association that was borderline statistically significant (P for trend 0.08). In addition, inverse associations with AF were observed (hazard ratio, 95% confidence interval for top versus bottom quintile, P value) for the number of total VLDL particles: 0.78, 0.61 to 0.99, 0.04, and in particular for small VLDL: 0.78, 0.62 to 0.99, 0.04.
Associations of VLDL and triglyceride measures with AF
In unadjusted models (Table 4) , only small HDL particles were significantly associated with AF. However, this attenuated and was no longer statistically significant after adjustment. Other HDL measures did not meet the threshold for statistical significance. To compare with prior studies, 6, 14, 15 we conducted an analysis for HDL cholesterol dichotomized at 1.30 mmol/L (50 mg/dL). Compared with women with an HDL cholesterol <1.30 mmol/L, women with an HDL cholesterol ≥1.30 mmol/L had a fully adjusted (Model 2) hazard ratio of 1.02, 95% confidence interval 0.87 to 1.20, and P value of 0.81.
Discussion
In this study, paradoxical associations with incident AF for LDL cholesterol as well as several other atherogenic lipoprotein measures emerged after multivariable adjustment. Specifically, the total number of LDL and VLDL particles was inversely associated with AF after multivariable adjustment. These associations were mostly driven by the cholesterol-poor small LDL and small VLDL particles. By contrast, the larger cholesterol-rich LDL particles (intermediate-density lipoprotein, large LDL, and lipoprotein [a]) and HDL measures were not independently associated with AF.
The inverse association between LDL cholesterol and AF in this study is consistent with prior prospective studies. 2, 5, 6 We also report for the first time an inverse association for AF with the total number of LDL and VLDL particles, mainly because of small LDL and VLDL. VLDL particles are triglyceride-carrying particles which, when subjected to further lipolysis, give rise to small LDL. 16 One previously hypothesized explanation for the association between LDL and AF relates to the stabilizing effect of cholesterol on myocardial cell membranes, which may impact ion channel density and function and other aspects of membrane excitability. 7, [17] [18] [19] [20] While our study is epidemiological, the inverse association of AF with cholesterol-poor small LDL and small VLDL rather than with the larger, cholesterol-enriched particles suggests that there are likely mechanisms beyond direct cholesterol effects underlying the observed association between LDL cholesterol and AF.
Given the lack of evidence for a direct cholesterol effect in our data, other mechanisms might underlie the observed association. Standard AF risk factors, such as hypertension and diabetes mellitus, are unlikely to account for our findings because the pattern of lipoprotein associations with these risk factors is the opposite from that observed for AF. 21, 22 In addition, control for these risk factors either strengthened or did not significantly impact the observed inverse association. The inverse associations also remained after adjustment for multiple inflammatory and dysglycemic biomarkers suggesting that the underlying mechanisms are also independent of such pathways. It is also important to note that although LDL cholesterol is inversely associated with AF, AF is not inversely associated with other outcomes associated with LDL such as myocardial infarction and stroke in this and other populations. Presumably, the prothrombotic milieu triggered or associated with AF outweighs any favorable associations with lipids on these atherothrombotic end points. In contrast, subclinical disorders of thyroid function, which were not measured in our study, may present one plausible intermediary mechanism. 23, 24 Hyperthyroidism, which is directly associated with AF, 23 reduces VLDL secretion, results in smaller VLDL, 25 and reduces LDL cholesterol, but has less of an effect on HDL cholesterol and lipoprotein(a). 26 On the other hand, hypothyroidism, which is associated with a lower risk of AF, 24 is associated with higher levels of remnant lipoproteins, including small VLDL and triglycerides, without affecting LDL size, 26 and may be a potential mediator of the association of small VLDL with AF. It is also feasible that lipoprotein components of LDL and VLDL, which are both expressed and secreted by myocardial cells, may have a direct influence on cardiac electrophysiology by protecting against excessive myocardial lipid accumulation. 27, 28 As in prior studies, 5,6 triglycerides were not associated with AF in adjusted models. Prior studies have been inconsistent on the association of HDL cholesterol with AF. While some found an inverse association, 5, 14, 15, [29] [30] [31] [32] others found no association. 6, 33, 34 These mixed results for HDL cholesterol may be related in part to the choice of covariables included in models. We found no association for HDL-related measures including HDL cholesterol, the number of HDL particles and subclasses, HDL size, and apoA-I.
Strengths of this study include the large sample size with well-characterized study participants, long prospective follow-up, extensive biomarker phenotyping, and confirmed events. However, the generalizability of our results to men is unclear, though traditional lipids have been found to associate with AF similarly in women and men. 35 The generalizability of our findings may be limited to women with a low prevalence of risk factors and comorbid conditions, although the association of LDL cholesterol and other risk factors with AF is similar to that observed in other populations. Several risk factors were assessed by self-report, and only a single baseline measurement of the lipoproteins was available. Without continuous ECG monitoring, it is also possible that asymptomatic AF cases may have gone undetected. Finally, we cannot rule out residual confounding. In summary, the inverse association between LDL cholesterol and AF extended to several other atherogenic lipoproteins. These associations are unlikely to be mediated by direct cholesterol effects as they were driven by the number of small cholesterol-poor LDL and VLDL particles. Future studies focused on the noncholesterol components of lipoproteins are needed to determine the underlying mechanisms of these associations.
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